Drugs / sNN0029
sNN0029
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02269436 | Jan → Oct 2015 | amyotrophic lateral sclerosis | Newron Sweden AB | Terminated | No outcome recorded |
| Phase 1 | NCT01999803 | Sep 2014 → Oct 2015 | amyotrophic lateral sclerosis | Newron Sweden AB | Terminated | No outcome recorded |
| Phase 1 | NCT00069446 | Aug 2003 → Oct 2004 | ulcer of lower limbs | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01384162 | Jun 2009 → Oct 2015 | amyotrophic lateral sclerosis | Newron Sweden AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT00800501 | Dec 2008 → Jun 2011 | amyotrophic lateral sclerosis | Newron Sweden AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00351767 | Jan 2006 → Jan 2008 | ulcer of lower limbs | Genentech, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-01-15 | Newron Pharmaceuticals SPA | Newron initiates Phase II study of sNN0029 in patients with Amyotrophic Lateral Sclerosis newron.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sNN0029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269436 ↗ |
| Known as | rhuMAb VEGF | “rhuMAb VEGF (telbermin)” NCT00069446 ↗ |
| Known as | telbermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00351767 ↗ |
| Known as | VEGF165 | “This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the...” NCT00800501 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Vascular Endothelial Growth Factor” NCT00069446 ↗ |
| Route | Topical | “Topical Recombinant Human Vascular Endothelial Growth Factor” NCT00069446 ↗ |